<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell E Ware, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3505766839"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autoimmune hemolytic anemia (AIHA) is a collection of disorders characterized by the presence of autoantibodies that bind to the patient's own erythrocytes, leading to premature red cell destruction due to hemolysis and, when the rate of hemolysis exceeds the ability of the bone marrow to replace the destroyed red cells, to anemia and its attendant signs and symptoms. AIHA is generally categorized as "warm" or "cold" based on the thermal reactivity of the autoantibodies (<a class="graphic graphic_table graphicRef55710" href="/z/d/graphic/55710.html" rel="external">table 1</a>) and is classified as primary (idiopathic) or secondary based on whether or not an underlying disease process is present (<a class="graphic graphic_table graphicRef57399" href="/z/d/graphic/57399.html" rel="external">table 2</a>).</p><p>The treatment and prognosis of AIHA in children are reviewed here. A general overview of hemolytic anemias in childhood is presented separately, as are other aspects related to AIHA, including pathophysiology, classification, clinical presentation, and diagnosis, as well as the diagnosis and management of paroxysmal cold hemoglobinuria (PCH):</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Pathogenesis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="headingAnchor" id="H3538760595"><span class="h1">GENERAL TREATMENT PRINCIPLES</span><span class="headingEndMark"> — </span>AIHA in children is relatively rare, and, therefore, available studies concerning the treatment of AIHA in children are generally small, retrospective, and/or anecdotal. Randomized controlled studies are entirely lacking. Optimal treatment of a child with AIHA depends initially upon the:</p><p class="bulletIndent1"><span class="glyph">●</span>Severity and chronicity of anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Degree of signs and symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Characteristics of the autoantibodies (<a class="graphic graphic_table graphicRef55710" href="/z/d/graphic/55710.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Nature of the underlying disease, if present (<a class="graphic graphic_table graphicRef57399" href="/z/d/graphic/57399.html" rel="external">table 2</a>)</p><p></p><p>Children with AIHA can be managed in the ambulatory setting if the anemia is not severe and there are no signs of cardiovascular compromise. At the time of initial disease presentation, however, hospitalization may be warranted to expedite the diagnostic evaluation, closely monitor the patient, and begin therapy before the anemia worsens.</p><p class="headingAnchor" id="H2811052291"><span class="h1">SEVERE OR LIFE-THREATENING ANEMIA</span><span class="headingEndMark"> — </span>There is no consensus regarding the threshold for transfusion in AIHA; the decision to transfuse depends upon the degree and onset of anemia. Rarely, the anemia in a child with AIHA is severe and causes cardiovascular compromise (eg, when the hemoglobin is &lt;5 g/dL). In such cases, urgent treatment is required and includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cell (RBC) transfusion (following urgent discussion with blood bank personnel regarding blood compatibility), <strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacotherapy (glucocorticoids in patients with warm AIHA, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> in patients with cold AIHA) (see <a class="local">'Warm-reactive AIHA'</a> below and <a class="local">'Cold agglutinin disease'</a> below)</p><p></p><p>Although transfusion can lead to additional hemolysis in patients with AIHA, it must be emphasized that despite the risks, <strong>transfusion therapy should not be withheld from a patient with life-threatening anemia</strong>. For patients who require urgent or emergency transfusion, joint decision making by the clinician and transfusion medicine specialist should occur. (See  <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">"Red blood cell (RBC) transfusion in individuals with serologic complexity"</a>.)</p><p>Identification of compatible RBCs to transfuse into a child with AIHA can be difficult. Discussions with blood bank personnel should be initiated as early as possible in order to minimize delays in providing blood and to avoid misunderstandings concerning the degree to which available blood units are compatible with the patient. (See  <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">"Red blood cell (RBC) transfusion in individuals with serologic complexity", section on 'AIHA and concurrent alloantibodies'</a>.)</p><p>Acute symptomatic transfusion reactions are uncommon in children with AIHA who require RBC transfusions, even when transfusing "least incompatible" units of blood [<a href="#rid1">1</a>]. Because transfused donor cells survive in patients with AIHA similar to the patient's own erythrocytes, transfusion is generally helpful to ameliorate the signs and symptoms of anemia, even if the transfused erythrocytes last in the circulation for only a short period of time.</p><p>Severe hemolytic transfusion reaction is more likely in patients with cold-reactive autoantibodies that fix complement and cause intravascular hemolysis (<a class="graphic graphic_table graphicRef55710" href="/z/d/graphic/55710.html" rel="external">table 1</a>). In such patients, strategies to reduce the likelihood of a hemolytic transfusion reaction include:</p><p class="bulletIndent1"><span class="glyph">●</span>Warming the blood to 37°C before and during the infusion</p><p class="bulletIndent1"><span class="glyph">●</span>Beginning the transfusion at a slow rate and checking both plasma and urine samples periodically for the presence of free hemoglobin</p><p></p><p>On the rare occasion when a transfusion results in more severe hemolysis, with substantial hemoglobinemia and hemoglobinuria, vigorous hydration should be provided to help prevent renal dysfunction.</p><p>Transfusions are required at some point in approximately 65 percent of children with AIHA [<a href="#rid2">2,3</a>]; however, in some cases, particularly those with active reticulocytosis, transfusion is not necessary.</p><p class="headingAnchor" id="H2305337498"><span class="h1">PAROXYSMAL COLD HEMOGLOBINURIA</span><span class="headingEndMark"> — </span>Children with paroxysmal cold hemoglobinuria (PCH) usually have an abrupt but self-limited hemolytic process. Keeping the patient warm and avoiding exposure to cold fluids are the mainstays of management. Transfusion may be required at presentation, particularly in patients with severe anemia. Treatment of PCH is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1451594257"><span class="h1">COLD AGGLUTININ DISEASE</span><span class="headingEndMark"> — </span>Most pediatric cases of cold agglutinin (immunoglobulin M [IgM]) AIHA are due to <em>Mycoplasma pneumoniae</em> or Epstein-Barr virus infection. The anemia tends to be mild at physiologic temperatures, and pharmacologic therapy is not necessary in most cases. As with PCH, management involves keeping the patient warm and avoiding exposure to cold fluids. Treatment of the underlying cause (eg, antibiotics in the case of <em>Mycoplasma</em> infection) is also an important aspect of management. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Management'</a>.)</p><p>Pharmacologic therapy is warranted in patients with severe symptomatic anemia. <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a> is the agent used most commonly (this is an off-label use of this drug). Rituximab and other treatments for cold agglutinin disease are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Management'</a>.)</p><p>In addition to pharmacotherapy, transfusion may be warranted in patients with severe symptomatic anemia. (See <a class="local">'Severe or life-threatening anemia'</a> above.)</p><p class="headingAnchor" id="H1732425502"><span class="h1">WARM-REACTIVE AIHA</span></p><p class="headingAnchor" id="H2491750816"><span class="h2">Rationale for treatment</span><span class="headingEndMark"> — </span>In contrast with cold agglutinin disease and paroxysmal cold hemoglobinuria (PCH), which tend to have an acute onset but are generally self-limited diseases in children, warm-reactive AIHA typically has a more relapsing and chronic disease course and usually does not resolve without treatment. For this reason, we suggest initial pharmacotherapy for children with warm-reactive AIHA.</p><p class="headingAnchor" id="H332109890"><span class="h2">First-line therapy (glucocorticoids)</span><span class="headingEndMark"> — </span>Glucocorticoids are the first-line therapy for warm-reactive AIHA. Glucocorticoids are preferred over other therapies because the response is generally more rapid, short-term side effects are usually manageable, and there is greater experience with glucocorticoids in children with AIHA.</p><p class="headingAnchor" id="H4248897188"><span class="h3">Initial dose</span><span class="headingEndMark"> — </span>This initial dose is dependent on the severity of anemia:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe anemia</strong> – Children who present with severe and symptomatic anemia (eg, hemoglobin &lt;6 to 7 g/dL) requiring hospitalization are initially treated with intravenous <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">methylprednisolone</a> 0.5 to 1 mg/kg per dose every six to eight hours for the first 24 to 72 hours (after which they are transitioned to oral <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> at the dose provided below). Occasionally, pulse high-dose methylprednisolone (30 mg/kg with maximum dose of 1 g once daily for three days) may be warranted for the most severely affected patients, such as those with rapidly evolving and severe hemolysis [<a href="#rid4">4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild or moderate anemia</strong> – Children with mild or moderate anemia (eg, hemoglobin ≥7 to 8 g/dL) and appropriate reticulocytosis can be initially treated with oral <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> 2 mg/kg per day in two or three divided doses.</p><p></p><p class="headingAnchor" id="H1270119031"><span class="h3">Tapering</span><span class="headingEndMark"> — </span>Steroid tapering in children with AIHA can be challenging, and relapse is common, particularly if the medication is tapered too quickly or discontinued abruptly [<a href="#rid3">3,7-10</a>]. (See <a class="local">'Response to treatment'</a> below.)</p><p>The goal of the taper is to minimize the risk of relapse while avoiding complications associated with long-term glucocorticoid use (eg, weight gain, growth impairment, psychiatric and cognitive symptoms, hypertension, hyperglycemia, osteoporosis, osteonecrosis of the femoral head, and cataracts). (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Our general approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First few months</strong> – Once an adequate response has been achieved (ie, hemoglobin &gt;9 to 10 g/dL), which typically occurs within two to four weeks, the steroid dose can be tapered to a single daily dose as tolerated over two to three months, based on serial evaluation of the hemoglobin concentration, reticulocyte count, lactate dehydrogenase (LDH), and direct antiglobulin test (DAT) results (see <a class="local">'Monitoring'</a> below). Most patients tolerate tapering <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> to a dose ≤1 mg/kg per day within this time frame. If this cannot be accomplished, a second-line therapy should be started to facilitate steroid weaning. (See <a class="local">'Second-line therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent tapering</strong> – Once the patient is tolerating a dose ≤1 mg/kg per day, <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> is slowly tapered but not stopped until there is normalization of the hemoglobin, reticulocyte count, and LDH/haptoglobin, although the DAT may remain weakly positive (see <a class="local">'Monitoring'</a> below). For most patients, the goal is to taper steroids off completely. However, some patients may require long-term, low-dose prednisone (ie, ≤0.2 mg/kg per day) to avoid remission. Patients who chronically require doses &gt;0.2 mg/kg per day and those who experience frequent relapses should generally be started on a second-line therapy. (See <a class="local">'Second-line therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H1294789302"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Monitoring of patients with AIHA consists of regular clinical assessments and laboratory testing, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin level</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>LDH</p><p class="bulletIndent1"><span class="glyph">●</span>DAT (previously called the Coombs test)</p><p></p><p>The frequency of monitoring depends on disease severity and treatment. In the outpatient setting, laboratory studies are typically monitored once weekly, initially, particularly to guide the early tapering of glucocorticoids. The interval between testing can be gradually increased as the clinical picture stabilizes, but monitoring should continue until the hemoglobin level and reticulocyte count have returned to normal (ie, hemoglobin ≥11 g/dL, reticulocyte count ≤100 × 10<sup>3</sup>/microL) and the patient is stable on low-dose glucocorticoids. LDH and DAT can be tested periodically, especially after the initial therapeutic response.</p><p>We typically continue monitoring patients for one year after remission has been achieved as the risk of relapse is greatest during this time. The DAT may remain weakly positive, even after complete remission has been attained. A persistent positive DAT suggests ongoing autoimmune disease and warrants further exploration for secondary etiologies such as Evans syndrome or systemic lupus erythematosus (SLE). (See  <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis", section on 'Evaluation for secondary causes'</a>.)</p><p class="headingAnchor" id="H1840493854"><span class="h3">Response to treatment</span><span class="headingEndMark"> — </span>Children with immunoglobulin G (IgG) warm-reactive AIHA tend to have a chronic disease course characterized by intermittent relapses.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expected response</strong> – Approximately 70 to 80 percent of patients have an initial response to glucocorticoid therapy [<a href="#rid3">3,7,10</a>]. The initial treatment response is a stabilization of the hemoglobin concentration, followed by a slow increase in the hemoglobin level and decreased reticulocytosis. Glucocorticoids have a rapid effect, within 24 to 48 hours, likely due to inhibition of the Fc receptor-mediated clearance of sensitized erythrocytes [<a href="#rid11">11</a>]. They also diminish the production of autoantibodies, but this effect requires several weeks.</p><p></p><p class="bulletIndent1">In one study of 246 pediatric patients with AIHA who were initially treated with glucocorticoids, hematologic recovery occurred within one month in the majority of patients but three-quarters of the cohort required ≥6 months of treatment [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor response to initial therapy</strong> – A minority of patients have an inadequate response to treatment during the first one to two months and/or do not tolerate initial tapering of glucocorticoids (ie, require <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> doses &gt;1 mg/kg per day to maintain remission). Such patients should be started on a second-line treatment, as discussed below. (See <a class="local">'Second-line therapies'</a> below.)</p><p></p><p class="bulletIndent1">In one series of 265 pediatric patients with AIHA, 37 percent required multimodal therapy [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapses</strong> – Relapses are common in patients with AIHA, occurring in 15 to 40 percent of patients in the initial six months to one year after initial response [<a href="#rid2">2,3,7,10</a>]. Treatment of relapses generally involves restarting the lowest <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> dose that was previously effective in maintaining the patient in remission. Patients with frequent relapses, and those in whom remission cannot be maintained off of prednisone or on a low prednisone dose (≤0.2 mg/kg per day), should generally be started on a second-line therapy. (See <a class="local">'Second-line therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H2204592855"><span class="h2">Refractory disease</span></p><p class="headingAnchor" id="H3866227046"><span class="h3">Second-line therapies</span><span class="headingEndMark"> — </span>Second-line treatment options for children with AIHA refractory to or dependent on glucocorticoids include <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> and splenectomy. Limited data on the use of rituximab in children and adults with AIHA are encouraging. For this reason, and because splenectomy in children is associated with a lifelong risk of sepsis and other potential complications (especially thrombosis, including portal vein thrombosis) [<a href="#rid12">12,13</a>], our practice is to treat with rituximab before resorting to splenectomy.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a> – Rituximab, which is an anti-CD20 monoclonal antibody, is our preferred second-line choice for treatment of children with AIHA refractory to or dependent on glucocorticoids. Rituximab is typically given in conjunction with steroid therapy in an attempt to allow weaning or even discontinuation of glucocorticoids. This is an off-label use of rituximab, based on one small prospective study and several case series in children with AIHA that have demonstrated response rates of 60 to 85 percent [<a href="#rid14">14-18</a>].</p><p></p><p class="bulletIndent1">The standard dose of <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> is 375 mg/m<sup>2</sup> per dose given intravenously once a week for four weeks. Some providers administer 750 mg/m<sup>2</sup> per dose as two doses two weeks apart.</p><p></p><p class="bulletIndent1">In a prospective study of 15 children with AIHA treated with <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, 13 children responded to therapy; most responded within two to four weeks [<a href="#rid15">15</a>]. Relapse occurred in three patients at 7 to 10 months after treatment. The children who relapsed were treated with a second course of rituximab and again achieved remission. Monitoring lymphocyte subpopulations every few months can help assess the treatment response. In our experience, relapse most commonly occurs when CD20-positive B cells recover.</p><p></p><p class="bulletIndent1">In some cases, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> therapy can induce prolonged absence of circulating B cells, especially CD19+27+ memory B cells, and profound hypogammaglobulinemia [<a href="#rid14">14</a>]. Replacement therapy with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) may be useful in patients who develop severe hypogammaglobulinemia after rituximab use [<a href="#rid15">15,19</a>]. Consultation with an immunologist may be beneficial. The authors' practice is to evaluate lymphocyte subpopulations and immunoglobulin levels prior to administering rituximab to ensure baseline evaluation is available if inadequate reconstitution should occur.</p><p></p><p class="bulletIndent1">Although the toxicity profile of <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> is generally favorable, rare infusion reactions can occur. Pretreatment with <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> and an antihistamine is standard practice. "Boxed Warnings" in the United States warn of severe infusion-related reactions, reactivation of hepatitis B infection, and severe mucocutaneous reactions, as well as progressive multifocal leukoencephalopathy, any one of which may be fatal. Most infusion reactions have occurred in association with the first infusion. Second and subsequent infusions can potentially be run at a more rapid rate in selected patients who tolerated the first infusion without any reactions or dose modifications [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenectomy</strong> – Splenectomy is an effective treatment for children with chronic or recalcitrant primary AIHA; approximately two-thirds of patients show a short-term improvement, usually evident within two weeks following surgery [<a href="#rid8">8,21,22</a>]. Splenectomy works by removing the main site of erythrocyte destruction (<a class="graphic graphic_figure graphicRef64888" href="/z/d/graphic/64888.html" rel="external">figure 1</a>) and also may benefit the patient with AIHA by removing a major site of autoantibody production.</p><p></p><p class="bulletIndent1">In a study of 52 adult and pediatric patients with AIHA who underwent splenectomy, an excellent response (no further steroid therapy) was reported in 64 percent and an improved status (with ongoing low-dose steroid therapy) in 21 percent [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">Because of the risk of post-splenectomy sepsis caused by encapsulated bacterial organisms in young children, splenectomy should be avoided in children &lt;3 years old and preferably delayed until &gt;6 years old.</p><p></p><p class="bulletIndent1">Patients undergoing splenectomy should receive appropriately timed preoperative immunization against <em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em>, and <em>Haemophilus influenzae</em> type b. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a>.)</p><p></p><p class="bulletIndent1">In addition, children who have undergone splenectomy should receive antibiotic prophylaxis and should be instructed to seek <strong>immediate</strong> medical attention in the event of fever due to the possibility of bacterial sepsis. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Emergency antibiotic supply'</a>.)</p><p></p><p class="bulletIndent1">Care should be taken to rule out secondary causes of AIHA prior to splenectomy. The risk of infection after splenectomy is markedly increased in some of the conditions that cause secondary AIHA (particularly autoimmune lymphoproliferative syndrome [ALPS], common variable immunodeficiency [CVID], and other immune deficiency and dysregulation syndromes). The procedure should be avoided when possible in these subgroups of patients. (See  <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis", section on 'Evaluation for secondary causes'</a>.)</p><p></p><p class="headingAnchor" id="H2228091124"><span class="h3">Third-line therapies</span><span class="headingEndMark"> — </span>For children with refractory AIHA who have failed therapy with glucocorticoids, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, and/or splenectomy and for those who remain steroid dependent despite treatment with rituximab and/or splenectomy, more aggressive therapy may be required. Several treatment options are available for such children, although each is less effective than either glucocorticoids, rituximab, or splenectomy. The aim of adjunctive therapy is generally to reduce or eliminate the need for continued steroid therapy (ie, "steroid-sparing" effect) since the long-term use of glucocorticoids is associated with unacceptable side effects in children. Decisions regarding adjuvant therapy should be individualized for each patient, based upon the hematologic response and side-effects.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> – IVIG has been used in pediatric and adult patients with AIHA; however, only approximately 30 percent of children respond and, in those that do, the effect is usually transient [<a href="#rid24">24,25</a>]. Replacement IVIG therapy may be warranted in children who develop clinically significant hypogammaglobulinemia as a consequence of treatment with <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>. (See <a class="local">'Second-line therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13199" href="/z/d/drug information/13199.html" rel="external">Danazol</a> – Danazol is a semisynthetic androgen that can reduce cell-bound IgG and complement and decrease IgG production [<a href="#rid26">26</a>]. Limited data in adults suggest that danazol use in combination with <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> may help reduce the prednisone dose in glucocorticoid-dependent patients [<a href="#rid27">27</a>]. The drug has not been studied in children with AIHA. The primary adverse side effects of danazol are elevations in the hepatic transaminases and mild masculinizing effects; as a result, females typically do not tolerate use of this agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">Azathioprine</a><strong> and </strong><a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">6-mercaptopurine</a> – 6-mercaptopurine and its prodrug, azathioprine, are immunosuppressive agents that primarily affect T lymphocyte helper function, thereby diminishing autoantibody synthesis and exerting a steroid-sparing effect. Clinical responses to either agent may require more than two to three months of therapy [<a href="#rid8">8,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">Cyclosporine</a> – Cyclosporine A is another immunosuppressive agent that also primarily affects T lymphocytes. Long-term use of cyclosporine has been associated with nephrotoxicity, hypertension, and a risk of second malignancy, and it should be reserved for children with refractory AIHA. The suggested starting oral dose is in the range of 1 to 3 mg/kg per day divided into two doses 12 hours apart.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">Mycophenolate</a><strong> mofetil, </strong><a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">tacrolimus</a><strong>, and </strong><a class="drug drug_pediatric" data-topicid="12761" href="/z/d/drug information/12761.html" rel="external">sirolimus</a> – These immunosuppressive agents have been employed in patients with relapsed, resistant AIHA, including those following solid organ or stem cell transplantation, or complicated by Evans syndrome, acquired pure red cell aplasia, and/or ALPS [<a href="#rid29">29-34</a>]. As with <a class="drug drug_pediatric" data-topicid="13199" href="/z/d/drug information/13199.html" rel="external">danazol</a>, their use may allow "steroid sparing," resulting in reduced doses of glucocorticoids required to maintain remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytotoxic agents</strong> – Cytotoxic agents that can reduce autoantibody formation include <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">vincristine</a>, <a class="drug drug_pediatric" data-topicid="12881" href="/z/d/drug information/12881.html" rel="external">vinblastine</a>, and <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>. Although few data exist on their efficacy in children with AIHA, these agents can be considered for the extremely refractory patient [<a href="#rid35">35,36</a>]. These agents generally are myelosuppressive and potentially mutagenic, and they should be used with caution in children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoclonal antibodies</strong> – A number of monoclonal antibodies targeting various lymphocyte antigens have been suggested as potential therapies for refractory AIHA [<a href="#rid37">37,38</a>]. Such targeted therapies hold promise; however, for the most part, the data supporting these agents in this setting are limited to case reports and small case series.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other anti-CD20 monoclonal antibodies – After the success of <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, other anti-CD20 monoclonal antibodies such as <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a> have been developed. These agents have enhanced ability to bind FcRIIIa and their use has been reported in small numbers of patients with refractory AIHA [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anti-CD52 monoclonal antibody – <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a>, a humanized anti-CD52 monoclonal antibody, targets predominantly T and B lymphocytes and has been reported in a few small case series [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bortezomib</strong> – <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a> is a proteasome inhibitor that depletes circulating plasma cells and affects antigen presentation. Its use in refractory AIHA has been described in small case series [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fostamatinib</strong> – <a class="drug drug_general" data-topicid="117669" href="/z/d/drug information/117669.html" rel="external">Fostamatinib</a> is a spleen tyrosine kinase (Syk) inhibitor. It has been studied in adults with AIHA but not children [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis</strong> – Plasmapheresis may be used as adjunctive treatment in patients with cold agglutinin (IgM-mediated) AIHA; however, its use in warm AIHA is considered a category III intervention (ie, disorders for which the optimum role of apheresis therapy is not established). (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'ASFA therapeutic categories'</a> and  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic cell transplantation</strong> – Successful hematopoietic cell transplantation for AIHA has been reported, including a single case report of a child with AIHA [<a href="#rid43">43-45</a>]. This treatment option is reserved for patients with severe disease in whom all other therapies have failed and for whom a thorough investigation for underlying treatable genetic disorders driving immune dysregulation has been nondiagnostic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complement inhibitors </strong>– Some cases of refractory AIHA feature complement-mediated erythrocyte destruction. In these cases, agents designed to inhibit the complement cascade have anecdotally been used (eg, <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a>, <a class="drug drug_general" data-topicid="131650" href="/z/d/drug information/131650.html" rel="external">pegcetacoplan</a>, <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>) [<a href="#rid46">46</a>]. There is a substantial risk of developing serious bacterial infections while on treatment, especially infections due to <em>Neisseria meningitis</em>. Thus, patients receiving complement inhibitor therapy should receive vaccinations for <em>N. meningitis</em>, <em>Streptococcus pneumoniae,</em> and <em>Haemophilus influenza</em> type b prior to starting therapy. (See  <a class="medical medical_review" href="/z/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria", section on 'Complement inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H316545197"><span class="h2">Secondary AIHA</span><span class="headingEndMark"> — </span>The above treatment recommendations apply to patients with primary and secondary AIHA. For some causes of secondary AIHA, there are additional important management considerations.</p><p class="headingAnchor" id="H4161396502"><span class="h3">Evans syndrome</span><span class="headingEndMark"> — </span>Evans syndrome is characterized by AIHA, immune thrombocytopenia (ITP), and/or autoimmune neutropenia. Some patients present with isolated AIHA and then develop additional cytopenias months or even years after the initial clinical presentation. The management of children with Evans syndrome is challenging as many patients are refractory to glucocorticoid therapy and require multimodal therapy. The most commonly used agents are glucocorticoids and <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> [<a href="#rid22">22</a>]. Because patients with Evans syndrome have concurrent ITP, IVIG is used more commonly to treat these patients compared with patients with isolated AIHA. (See  <a class="medical medical_review" href="/z/d/html/5917.html" rel="external">"Immune thrombocytopenia (ITP) in children: Initial management", section on 'Intravenous immune globulin'</a>.)</p><p><a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a>, <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_pediatric" data-topicid="12761" href="/z/d/drug information/12761.html" rel="external">sirolimus</a>, and various monoclonal antibodies described above may be effective therapeutic agents as well [<a href="#rid34">34,39</a>]. (See <a class="local">'Second-line therapies'</a> above and <a class="local">'Third-line therapies'</a> above.)</p><p>Although some patients with Evans syndrome initially respond to glucocorticoids, most relapse after stopping therapy and adjuvant or alternative therapy is often required. In the previously described study of 265 children with AIHA, 65 percent of children with Evans syndrome required multimodal therapy (compared with only 37 percent of children with isolated AIHA) [<a href="#rid3">3</a>]. <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a> appears to be an effective second-line treatment for children with Evans syndrome. In a retrospective study of 17 children with Evans syndrome, rituximab therapy in combination with <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> (14 patients) or other immunosuppressive drugs (3 patients) was associated with complete or partial remission in 13 patients (76 percent) [<a href="#rid47">47</a>]. Relapse occurred in 3 patients at a median follow-up of 2.4 years. Glucocorticoid therapy was able to be discontinued or tapered to &lt;50 percent of the baseline dose in all long-term responders.</p><p>Splenectomy can improve cytopenias in patients with Evans syndrome, but the response rate is lower than in patients with isolated AIHA or ITP [<a href="#rid22">22</a>]. In addition, relapses following splenectomy are common. For this reason, splenectomy is typically reserved for patients who fail medical therapy.</p><p>A substantial proportion of children who present with Evans syndrome actually have ALPS as the underlying etiology of their immune dysregulation [<a href="#rid48">48</a>]. For this reason, it is imperative that all children who present with AIHA and another cytopenia be screened for ALPS. (See  <a class="medical medical_review" href="/z/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H1361705404"><span class="h3">Immunodeficiency</span><span class="headingEndMark"> — </span>AIHA may occur in patients with primary immunodeficiency, such as CVID, Wiskott-Aldrich syndrome, CTLA4 haploinsufficiency with autoimmune infiltration disease, LRBA deficiency, and <em>STAT3</em> gain-of function mutations. It also can occur with acquired immunodeficiency (eg, HIV infection). Treatment of AIHA in patients with underlying immunodeficiency is similar to treatment of primary AIHA, and most patients respond to glucocorticoid therapy. However, with the increasing availability of targeted therapies for some genetic mutations, the frontline response rates may improve with successful control of immune dysregulation. Severe infections can occur following splenectomy or <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> therapy in patients with underlying immunodeficiency, particularly CVID [<a href="#rid22">22</a>]. Close monitoring for infectious complications during treatment is advised in these patients.</p><p class="headingAnchor" id="H1510177604"><span class="h3">Autoimmune lymphoproliferative syndrome</span><span class="headingEndMark"> — </span>ALPS is characterized by dysregulation of the immune system due to an inability to regulate lymphocyte maturation and clonal expansion. The consequences of this include lymphoproliferative disease (eg, lymphadenopathy, hepatomegaly, splenomegaly, lymphoma) and autoimmune disease, typically involving blood cells.</p><p>Development of AIHA in patients with ALPS often signals a transition in the natural history and the need to initiate or escalate therapy. Patients with autoimmune manifestations typically have a more difficult time coming off of immunosuppressive therapy than patients with lymphoproliferation only. A combination of immunosuppressive and immunomodulating agents (eg, glucocorticoids, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>, <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">mycophenolate</a>, and <a class="drug drug_pediatric" data-topicid="12761" href="/z/d/drug information/12761.html" rel="external">sirolimus</a>) may be necessary in these patients.</p><p>Treatment of ALPS is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/16614.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis", section on 'Autoimmune manifestations'</a>.)</p><p class="headingAnchor" id="H233058471"><span class="h3">Systemic lupus erythematosus</span><span class="headingEndMark"> — </span>Patients with SLE who have mild to moderate AIHA can generally be treated with <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> as described above (see <a class="local">'First-line therapy (glucocorticoids)'</a> above). It should be noted that the DAT may be weakly positive in SLE without evidence of clinical or laboratory hemolysis, and such patients are generally not considered to have AIHA.</p><p>Cases of severe rapidly progressive anemia may require high-dose intravenous <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">methylprednisolone</a> (30 mg/kg per day for three days; maximum daily dose 1 g), followed by tapering daily oral doses of <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> as the response to therapy allows. Patients with SLE and other autoimmune disease-induced AIHA may benefit from earlier initiation of <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> therapy. (See  <a class="medical medical_review" href="/z/d/html/98076.html" rel="external">"Systemic lupus erythematosus (SLE) in children: Treatment, complications, and prognosis"</a>.)</p><p class="headingAnchor" id="H3532672106"><span class="h3">Drug-induced autoimmune hemolytic anemia</span><span class="headingEndMark"> — </span>In patients with suspected drug-induced AIHA (<a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">table 3</a>), it is imperative that the offending drug be discontinued. In many cases, corticosteroids are used to slow the rate of hemolysis and plasmapheresis can be considered if the patient has clinical deterioration. (See  <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia", section on 'Management'</a>.)</p><p class="headingAnchor" id="H3669421803"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2480326750"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Reported mortality rates in contemporary case series range from 3 to 4 percent [<a href="#rid2">2,3</a>]. Mortality rates in earlier case series were considerably higher (10 to 15 percent) [<a href="#rid49">49-51</a>]. The main causes of death in these reports were overwhelming sepsis in splenectomized patients, catastrophic bleeding in patients with Evans syndrome (ie, concurrent immune thrombocytopenia [ITP]), and complications of underlying diseases (eg, malignancy or immunodeficiency syndromes). The lower mortality rate observed in the later studies may reflect improvements in supportive care (particularly post-splenectomy care) and improvements due to newer therapies (eg, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, <a class="drug drug_pediatric" data-topicid="12761" href="/z/d/drug information/12761.html" rel="external">sirolimus</a>).</p><p class="headingAnchor" id="H2127508995"><span class="h2">Remission</span><span class="headingEndMark"> — </span>Patients with paroxysmal cold hemoglobinuria (PCH) and cold agglutinin disease secondary to <em>M. pneumoniae</em> or Epstein-Barr virus infection tend to have a self-limited course, and, although the acute presentation may be severe, the long-term outcome is generally good and most patients make a complete recovery within weeks to a few months after disease onset. (See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a> and  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Clinical manifestations'</a>.)</p><p>In contrast, children with IgG warm-reactive AIHA tend to have a chronic disease course characterized by intermittent relapses. (See <a class="local">'Response to treatment'</a> above.)</p><p>In the largest series of children with AIHA, involving 265 patients followed for a median of 3 years, 90 percent had achieved complete remission at the time of last follow-up [<a href="#rid3">3</a>]. Of the patients who achieved remission, 44 percent had maintained stable complete remission without any specific treatment for &gt;1 year; 29 percent still required therapy to maintain remission. Mean duration of therapy was 1.6 years among children with isolated AIHA and 4.3 years among children with Evans syndrome.</p><p>Factors associated with poor prognosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Family or personal history of immunodeficiency or autoimmune disease</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent thrombocytopenia or lymphocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Positive direct antiglobulin test (DAT) for both IgG and complement component 3</p><p></p><p>In contrast, abrupt onset of symptoms and documented infection at the time of diagnosis are associated with a greater likelihood of complete remission.</p><p class="headingAnchor" id="H2138597376"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83062.html" rel="external">"Patient education: Autoimmune hemolytic anemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1034308887"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment principles</strong> – Optimal treatment of a child with autoimmune hemolytic anemia (AIHA) depends initially upon the severity and chronicity of the anemia, signs and symptoms, characteristics of the autoantibodies (<a class="graphic graphic_table graphicRef55710" href="/z/d/graphic/55710.html" rel="external">table 1</a>), and nature of the underlying disease if present (<a class="graphic graphic_table graphicRef57399" href="/z/d/graphic/57399.html" rel="external">table 2</a>). (See <a class="local">'General treatment principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe or life-threatening anemia</strong> – Children with AIHA who present with severe anemia of sudden onset that is associated with cardiovascular compromise require urgent red blood cell (RBC) transfusion, which requires prompt discussion with blood bank personnel. Although transfusion can lead to additional hemolysis in patients with AIHA, it must be emphasized that, despite the risks, <strong>transfusion therapy should not be withheld from a patient with life-threatening anemia</strong>. (See <a class="local">'Severe or life-threatening anemia'</a> above and  <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">"Red blood cell (RBC) transfusion in individuals with serologic complexity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paroxysmal cold hemoglobinuria (PCH)</strong> – Children with PCH usually have a self-limited hemolytic process. Keeping the patient warm and avoiding exposure to cold fluids are the mainstays of management. Transfusion may be required in patients with severe anemia. Treatment of PCH is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold agglutinin disease</strong> – Most pediatric cases of cold agglutinin AIHA are due to <em>Mycoplasma pneumoniae</em> or Epstein-Barr virus infection. The anemia tends to be mild, and pharmacologic therapy is not necessary in most cases. Management involves keeping the patient warm and avoiding exposure to cold fluids. Pharmacologic therapy and/or transfusion is warranted in patients with severe symptomatic anemia. <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a> is the most commonly used agent. Treatment of the underlying cause (eg, antibiotics in the case of <em>Mycoplasma</em> infection) is also an important aspect of management. Treatment of cold agglutinin AIHA is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warm-reactive AIHA</strong> – For most children with warm-reactive AIHA, we suggest initial pharmacotherapy with glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In contrast with cold agglutinin disease and PCH, which tend to be self-limited diseases in children, warm-reactive AIHA typically has a more chronic disease course and usually does not resolve without therapy. For most patients, we suggest glucocorticoids for first-line therapy rather than other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) because the response is generally more rapid, short-term side effects are usually manageable, and there is greater experience with glucocorticoids in children with AIHA. (See <a class="local">'Rationale for treatment'</a> above and <a class="local">'First-line therapy (glucocorticoids)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory AIHA</strong> – Most patients with warm-reactive AIHA respond to initial therapy with glucocorticoids, though relapses are common. For patients with refractory AIHA (ie, failure to respond to glucocorticoid therapy within one to two months or unable to taper off or to low-dose <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>), we suggest <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> rather than splenectomy as the preferred second-line treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is because splenectomy in children is associated with a lifelong risk of sepsis and other potential complications (eg, portal vein thrombosis). (See <a class="local">'Response to treatment'</a> above and <a class="local">'Second-line therapies'</a> above.)</p><p></p><p class="bulletIndent1">Third-line treatment options for patients who remain steroid dependent despite treatment with <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> and/or splenectomy include intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG), <a class="drug drug_pediatric" data-topicid="13199" href="/z/d/drug information/13199.html" rel="external">danazol</a>, immunosuppressive agents (eg, <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">azathioprine</a>, <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">6-mercaptopurine</a>, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>, <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">tacrolimus</a>, <a class="drug drug_pediatric" data-topicid="12761" href="/z/d/drug information/12761.html" rel="external">sirolimus</a>), cytotoxic agents (eg, <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">vincristine</a>, <a class="drug drug_pediatric" data-topicid="12881" href="/z/d/drug information/12881.html" rel="external">vinblastine</a>, <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>), complement blocking agents, plasmapheresis, and hematopoietic cell transplantation. Data on these treatment modalities in children are extremely limited, and, in general, they appear to be less effective than glucocorticoids, rituximab, or splenectomy. (See <a class="local">'Third-line therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment considerations for the underlying disease</strong> – Secondary AIHA is treated in the same manner as primary AIHA; however, depending on the nature of the underlying disease, there may be additional important management considerations. (See <a class="local">'Secondary AIHA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The mortality rate in pediatric AIHA is approximately 3 to 4 percent. Long-term remission is achieved in approximately 90 percent of patients, though a substantial proportion require ongoing therapy to maintain remission. Factors associated with poor prognosis include family or personal history of immunodeficiency or autoimmune disease, concurrent thrombocytopenia or lymphocytopenia, and positive direct antiglobulin test (DAT) for both immunoglobulin G (IgG) and complement component 3. Abrupt onset of symptoms and documented infection at the time of diagnosis are associated with a good prognosis. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1131753806"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jenny Despotovic, DO, MS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Salama A, Berghöfer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340:1515.</a></li><li><a class="nounderline abstract_t">Sankaran J, Rodriguez V, Jacob EK, et al. Autoimmune Hemolytic Anemia in Children: Mayo Clinic Experience. J Pediatr Hematol Oncol 2016; 38:e120.</a></li><li><a class="nounderline abstract_t">Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011; 96:655.</a></li><li><a class="nounderline abstract_t">Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev 2010; 24:195.</a></li><li><a class="nounderline abstract_t">Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014; 99:1547.</a></li><li><a class="nounderline abstract_t">Jaime-Pérez JC, Rodríguez-Martínez M, Gómez-de-León A, et al. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp (Warsz) 2013; 61:385.</a></li><li><a class="nounderline abstract_t">Naithani R, Agrawal N, Mahapatra M, et al. Autoimmune hemolytic anemia in children. Pediatr Hematol Oncol 2007; 24:309.</a></li><li><a class="nounderline abstract_t">Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. Semin Hematol 1992; 29:64.</a></li><li><a class="nounderline abstract_t">Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol 2011; 4:607.</a></li><li><a class="nounderline abstract_t">Gupta V, Shukla J, Bhatia BD. Autoimmune hemolytic anemia. Indian J Pediatr 2008; 75:451.</a></li><li><a class="nounderline abstract_t">Fries LF, Brickman CM, Frank MM. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. J Immunol 1983; 131:1240.</a></li><li><a class="nounderline abstract_t">Luoto TT, Pakarinen MP, Koivusalo A. Long-term outcomes after pediatric splenectomy. Surgery 2016; 159:1583.</a></li><li><a class="nounderline abstract_t">Soyer T, Ciftci AO, Tanyel FC, et al. Portal vein thrombosis after splenectomy in pediatric hematologic disease: risk factors, clinical features, and outcome. J Pediatr Surg 2006; 41:1899.</a></li><li><a class="nounderline abstract_t">Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358:1511.</a></li><li><a class="nounderline abstract_t">Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101:3857.</a></li><li><a class="nounderline abstract_t">Kim JJ, Thrasher AJ, Jones AM, et al. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 2007; 138:94.</a></li><li><a class="nounderline abstract_t">Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011; 155:498.</a></li><li><a class="nounderline abstract_t">Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010; 47:170.</a></li><li><a class="nounderline abstract_t">Giulino LB, Bussel JB, Neufeld EJ, Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 2007; 150:338.</a></li><li><a class="nounderline abstract_t">Bernhardt MB, De Guzman MM, Grimes A, et al. Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">CHERTKOW G, DACIE JV. Results of splenectomy in auto-immune haemolytic anaemia. Br J Haematol 1956; 2:237.</a></li><li class="breakAll">Chou ST, Schreiber AD. Autoimmune hemolytic anemia. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Look T, et al (Eds), WB Saunders, 2015. p.411.</li><li><a class="nounderline abstract_t">Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch Surg 1985; 120:625.</a></li><li><a class="nounderline abstract_t">Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264.</a></li><li><a class="nounderline abstract_t">Vagace JM, Bajo R, Gervasini G. Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children. Arch Dis Child 2014; 99:668.</a></li><li><a class="nounderline abstract_t">Agnello V, Pariser K, Gell J, et al. Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement. J Rheumatol 1983; 10:682.</a></li><li><a class="nounderline abstract_t">Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993; 83:343.</a></li><li><a class="nounderline abstract_t">Sobota A, Neufeld EJ, Lapsia S, Bennett CM. Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer 2009; 52:80.</a></li><li><a class="nounderline abstract_t">Valentini RP, Imam A, Warrier I, et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant 2006; 10:358.</a></li><li><a class="nounderline abstract_t">Acquazzino MA, Fischer RT, Langnas A, Coulter DW. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor. Pediatr Transplant 2013; 17:466.</a></li><li><a class="nounderline abstract_t">Lauro A, Stanzani M, Finelli C, et al. Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant. Case Rep Transplant 2014; 2014:262953.</a></li><li><a class="nounderline abstract_t">Miano M, Calvillo M, Palmisani E, et al. Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol 2014; 167:571.</a></li><li><a class="nounderline abstract_t">Park JA, Lee HH, Kwon HS, et al. Sirolimus for Refractory Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review of the Treatment of Post-Transplant Autoimmune Hemolytic Anemia. Transfus Med Rev 2016; 30:6.</a></li><li><a class="nounderline abstract_t">Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 2016; 127:17.</a></li><li><a class="nounderline abstract_t">Ahn YS, Harrington WJ, Byrnes JJ, et al. Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets. JAMA 1983; 249:2189.</a></li><li><a class="nounderline abstract_t">Medellin PL, Patten E, Weiss GB. Vinblastine for autoimmune hemolytic anemia. Ann Intern Med 1982; 96:123.</a></li><li><a class="nounderline abstract_t">Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol 2018; 14:857.</a></li><li><a class="nounderline abstract_t">Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2018; 2018:382.</a></li><li><a class="nounderline abstract_t">Miano M. How I manage Evans Syndrome and AIHA cases in children. Br J Haematol 2016; 172:524.</a></li><li><a class="nounderline abstract_t">Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006; 91:ECR13.</a></li><li><a class="nounderline abstract_t">Ratnasingam S, Walker PA, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 2016; 1:31.</a></li><li class="breakAll">A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) (SOAR). Available at: https://clinicaltrials.gov/ct2/show/NCT02612558.</li><li><a class="nounderline abstract_t">Pession A, Zama D, Masetti R, et al. Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: is this a valid option? Pediatr Transplant 2012; 16:413.</a></li><li><a class="nounderline abstract_t">Passweg JR, Rabusin M. Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity 2008; 41:660.</a></li><li><a class="nounderline abstract_t">Paillard C, Kanold J, Halle P, et al. Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia. Br J Haematol 2000; 110:900.</a></li><li><a class="nounderline abstract_t">Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med 2021; 385:1407.</a></li><li><a class="nounderline abstract_t">Bader-Meunier B, Aladjidi N, Bellmann F, et al. Rituximab therapy for childhood Evans syndrome. Haematologica 2007; 92:1691.</a></li><li><a class="nounderline abstract_t">Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010; 115:2142.</a></li><li><a class="nounderline abstract_t">Heisel MA, Ortega JA. Factors influencing prognosis in childhood autoimmune hemolytic anemia. Am J Pediatr Hematol Oncol 1983; 5:147.</a></li><li><a class="nounderline abstract_t">Oliveira MC, Oliveira BM, Murao M, et al. Clinical course of autoimmune hemolytic anemia: an observational study. J Pediatr (Rio J) 2006; 82:58.</a></li><li><a class="nounderline abstract_t">Habibi B, Homberg JC, Schaison G, Salmon C. Autoimmune hemolytic anemia in children. A review of 80 cases. Am J Med 1974; 56:61.</a></li></ol></div><div id="topicVersionRevision">Topic 107301 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361607" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Red blood cell transfusion in warm-type autoimmune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925716" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autoimmune Hemolytic Anemia in Children: Mayo Clinic Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228033" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656187" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25271314" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of autoimmune hemolytic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23689532" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Current approaches for the treatment of autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613874" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autoimmune hemolytic anemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1570545" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment modalities of autoimmune blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077525" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classification and therapeutic approaches in autoimmune hemolytic anemia: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537006" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6224854" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26832988" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term outcomes after pediatric splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101367" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Portal vein thrombosis after splenectomy in pediatric hematologic disease: risk factors, clinical features, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705566" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of childhood autoimmune haemolytic anaemia with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531800" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498197" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21981575" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350664" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rituximab in autoimmune hematologic diseases: not just a matter of B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382107" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment with rituximab in benign and malignant hematologic disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28792663" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13342358" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Results of splenectomy in auto-immune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13342358" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Results of splenectomy in auto-immune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3985801" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Splenectomy in the treatment of hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2432727" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599068" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6606038" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8457484" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Danazol in autoimmune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18726904" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Response to mercaptopurine for refractory autoimmune cytopenias in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677361" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730873" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25177510" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975111" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26481836" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sirolimus for Refractory Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review of the Treatment of Post-Transplant Autoimmune Hemolytic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26504182" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6834615" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7053689" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vinblastine for autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30204521" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Current and emerging treatment options for autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504336" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26625877" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : How I manage Evans Syndrome and AIHA cases in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709521" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296693" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296693" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22519456" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: is this a valid option?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18958755" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054079" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34614331" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Autoimmune Hemolytic Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055994" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rituximab therapy for childhood Evans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20068224" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6193721" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Factors influencing prognosis in childhood autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16532149" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical course of autoimmune hemolytic anemia: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4809573" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Autoimmune hemolytic anemia in children. A review of 80 cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
